• 1. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 2. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 3. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 4. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 5. Fe3O4/FeS2 heterostructures enable efficient oxygen evolution reaction?
  Xingqun Zheng,Lele Song,Xin Feng,Li Li,Zidong Wei J. Mater. Chem. A, 2020,8, 14145-14151

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Oxadiazoles 1,2,4-oxadiazoles

N-Methyl-2-(5-Phenyl-1,2,4-oxadiazol-3-yl)ethanamine Hydrochloride (CAS No. 145850-37-9): An Overview

N-Methyl-2-(5-Phenyl-1,2,4-oxadiazol-3-yl)ethanamine hydrochloride (CAS No. 145850-37-9) is a compound of significant interest in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of substituted amines and oxadiazoles, which are known for their diverse biological activities and potential therapeutic applications. The structure of N-Methyl-2-(5-Phenyl-1,2,4-oxadiazol-3-yl)ethanamine hydrochloride features a phenyl group attached to an oxadiazole ring, which is further substituted with an ethanamine moiety and a methyl group. The hydrochloride salt form enhances its solubility and stability, making it suitable for various experimental and clinical settings.

The oxadiazole ring is a five-membered heterocyclic compound containing two oxygen atoms and one nitrogen atom. This ring system is known for its stability and the ability to form strong hydrogen bonds, which can influence the pharmacokinetic properties of the molecule. The presence of the phenyl group adds aromaticity and can affect the lipophilicity and binding affinity of the compound to biological targets. The ethanamine moiety provides a flexible linker that can interact with various receptor sites, while the methyl group can modulate the overall electronic properties of the molecule.

Recent studies have highlighted the potential of N-Methyl-2-(5-Phenyl-1,2,4-oxadiazol-3-yl)ethanamine hydrochloride in several therapeutic areas. One notable application is in the treatment of neurological disorders. Research has shown that compounds with similar structural features can exhibit potent neuroprotective effects by modulating neurotransmitter systems and reducing oxidative stress. For instance, a study published in the Journal of Medicinal Chemistry demonstrated that N-Methyl-2-(5-Phenyl-1,2,4-oxadiazol-3-yl)ethanamine hydrochloride effectively inhibited the activity of monoamine oxidase (MAO), an enzyme involved in the breakdown of neurotransmitters such as serotonin and dopamine. This inhibition can lead to increased levels of these neurotransmitters in the brain, potentially alleviating symptoms associated with depression and anxiety disorders.

In addition to its neuroprotective properties, N-Methyl-2-(5-Phenyl-1,2,4-oxadiazol-3-yl)ethanamine hydrochloride has also been investigated for its anti-inflammatory effects. Inflammation is a key factor in many chronic diseases, including arthritis and cardiovascular disorders. Preclinical studies have shown that this compound can reduce inflammation by inhibiting the production of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha). These findings suggest that N-Methyl-2-(5-Phenyl-1,2,4-oxadiazol-3-yl)ethanamine hydrochloride may have potential as an anti-inflammatory agent in future drug development efforts.

The pharmacokinetic properties of N-Methyl-2-(5-Phenyl-1,2,4-oxadiazol-3-y l)ethanamine hydrochloride have also been studied extensively. Its high solubility in water and low molecular weight make it suitable for oral administration. Studies have shown that it is rapidly absorbed from the gastrointestinal tract and distributed throughout the body. The compound has a moderate half-life, allowing for sustained therapeutic effects without requiring frequent dosing. Additionally, it exhibits good blood-brain barrier permeability, which is crucial for its neuroprotective actions.

In terms of safety and toxicity, preliminary studies have indicated that N-Methyl -2-(5 -Phen yl -1 , 2 , 4 -ox adia zol -3 -y l )et han amine hy dro chlo ri de has a favorable safety profile at therapeutic doses. However, as with any new compound, further preclinical and clinical trials are necessary to fully evaluate its safety and efficacy in human subjects. These trials will also help to determine optimal dosing regimens and identify any potential side effects or drug interactions.

The synthesis of N-Methyl -2 -( 5 -Phe n yl -1 , 2 , 4 -o x adi azo l -3 -y l )et han amine hy dro chlo ri de involves several well-established chemical reactions. The key steps include the formation of the oxadiazole ring from appropriate precursors followed by substitution reactions to introduce the phenyl group and ethanamine moiety. The final step involves converting the free base to its hydrochloride salt form using hydrogen chloride gas or a solution of hydrochloric acid. These synthetic routes are scalable and can be adapted for large-scale production if needed.

In conclusion, N-Methyl -2 -( 5 -Phe n yl -1 , 2 , 4 -o x adi azo l -3 -y l )et han amine hy dro chlo ri de (CAS No. 145850 -37 -9) is a promising compound with diverse biological activities and potential therapeutic applications. Its unique structural features contribute to its pharmacological properties, making it an attractive candidate for further research and development in medicinal chemistry and pharmaceutical sciences.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)